Highly Immunogenic, Universal COVID-19 Vaccine

Description

This technology is a novel, universal COVID-19 vaccine platform designed to greatly enhance the immune response to a wide variety of strains of SARS-CoV-2, including original, Delta, and Omicron. In-vivo studies show remarkable animal survival rates with no weight loss for a number of different SARS-CoV-2 variants.

As of April 2024, more than 884 million cases of COVID-19, caused by SARS-CoV-2 infection, have been reported globally, including more than 7 million deaths. New variants of the virus continue to emerge while the COVID-19 vaccine declines over time. It is estimated that the Delta variant has been 80% to 90% more transmissible than the Alpha variant.

Around 25% of the COVID-19 cases in the U.S. were caused by a new variant called KP.3 in the past 3 months. Therefore, it is critical to develop vaccines that remain highly effective against evolving strains, especially when the new strain is more aggressive, highly transmissible, and able to cause more severe diseases.

Benefits

• Highly Effective: In-vivo studies have demonstrated a 100% survival rate and no weight loss after being challenged with SARS-CoV-2 infections.
• Vigorous Immune Response: Significantly higher serum levels of neutralizing antibodies and reduced viral titers in the lungs after immunization.
• Flexible Platform: Flexible and adaptable vaccine structures enable adaptation to evolving virus variants, for ongoing effectiveness.

Applications

• COVID-19 Vaccines
• Platform to Develop Vaccines for Future Viral Threats

Patent Status

• PCT pending WO2024011163A1 - Coronavirus vaccines and methods of use thereof - Google Patents

Publications

mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern - ScienceDirect;

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection | Journal of Virology (asm.org);

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge - ScienceDirect

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern | npj Vaccines (nature.com)